Compare KARD & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KARD | DRTS |
|---|---|---|
| Founded | 2023 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2026 | 2021 |
| Metric | KARD | DRTS |
|---|---|---|
| Price | $14.10 | $12.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $41.00 | $17.80 |
| AVG Volume (30 Days) | ★ 577.7K | 443.8K |
| Earning Date | 11-22-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $50.00 | $1,235.59 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.23 | $3.43 |
| 52 Week High | $27.00 | $15.79 |
| Indicator | KARD | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 47.93 | 41.55 |
| Support Level | $13.75 | $11.24 |
| Resistance Level | $15.93 | $13.95 |
| Average True Range (ATR) | 0.99 | 0.63 |
| MACD | 0.32 | 0.00 |
| Stochastic Oscillator | 68.52 | 48.92 |
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.